HomeNBY • NYSEAMERICAN
Follow
NovaBay Pharmaceuticals Inc
Previous close
$0.082
Day range
$0.076 - $0.086
Year range
$0.071 - $1.95
Market cap
2.45M USD
Avg Volume
2.67M
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 3.73M | 2.31% |
Operating expense | 2.61M | -41.20% |
Net income | -4.11M | 49.94% |
Net profit margin | -110.22 | 51.07% |
Earnings per share | -1.33 | 9.67% |
EBITDA | -748.00K | 70.85% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.13M | -41.63% |
Total assets | 9.03M | -44.91% |
Total liabilities | 5.72M | -2.14% |
Total equity | 3.31M | — |
Shares outstanding | 30.10M | — |
Price to book | 0.68 | — |
Return on assets | -18.23% | — |
Return on capital | -24.80% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -4.11M | 49.94% |
Cash from operations | -314.00K | 74.03% |
Cash from investing | -2.00K | — |
Cash from financing | -26.00K | -100.86% |
Net change in cash | -342.00K | -118.73% |
Free cash flow | 758.25K | 593.57% |
About
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.
and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
Founded
2000
Headquarters
Website
Employees
25
